Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
Data shows testing with DecisionDx®-Melanoma provided significant prognostic information regarding survival outcomes
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in JCO Precision Oncology1 in which DecisionDx®-Melanoma provided significant, independent risk stratification of patients with cutaneous melanoma (CM), beyond American Joint Committee on Cancer Eighth Edition (AJCC8) stage, which may help inform more personalized patient management decisions. Additionally, data from the study shows that testing with DecisionDx-Melanoma was associated with lower melanoma-specific and overall mortality relative to untested patients. The study can be found here.
Castle